Safety and Efficacy of Regenerative Therapy: A Systematic Synthesis of Clinical Trials

Regenerative therapy has expanded rapidly across multiple medical fields, yet the translation of preclinical promise into consistent clinical benefit remains elusive. We conducted a systematic synthesis of clinical trials and case studies to evaluate safety, efficacy, health economic outcomes, and patient specific moderators of therapeutic response, focusing on mesenchymal stem cell applications, platelet rich plasma, and related interventions. Our methodology employed a multi component extraction framework across five research questions, drawing data from ClinicalTrials.gov and PubMed for randomized controlled trials, long term follow up studies, cost analyses, and outcome reporting standards. The evidence base varied substantially across outcomes: efficacy findings were primarily derived from six randomized controlled trials involving 80–420 participants, whereas long term safety, economic, and moderator analyses relied on smaller and more heterogeneous sets of observational follow up studies, case based evidence, and cost analyses. Accordingly, the strength of evidence was greatest for short to medium term efficacy outcomes and more limited for long term safety, cost effectiveness, and patient level moderators.The analysis identified six key randomized controlled trials with sample sizes ranging from 80 to 420 patients and follow up durations from six months to over three years. Efficacy varied considerably by cell source and administration route for example, autologous bone marrow derived mesenchymal stem cells delivered intracoronarily produced a 5.9 percent improvement in left ventricular ejection fraction, while allogeneic Wharton’s jelly cells yielded a hazard ratio of 0.43 for heart failure incidence. Long term safety data from studies with follow up exceeding ten years consistently showed no evidence of tumorigenicity or ectopic tissue formation. Health economic analysis revealed that platelet rich plasma in periodontal therapy incurred additional costs of 62 to 68 Malaysian ringgit per patient annually, with potential savings if outpatient visits were avoided. Patient specific moderators, including baseline C reactive protein levels and inflammatory immune state, significantly influenced therapeutic response. Outcome reporting analysis demonstrated that cardiac trials mixing surrogate imaging biomarkers with clinical endpoints produced more optimistic conclusions than analyses restricted to functional outcomes. This synthesis confirms acceptable long term safety profiles but highlights heterogeneous, indication dependent efficacy, with the strongest evidence in periodontal and select cardiac applications. Our findings identify critical gaps in trial design and reporting, providing actionable insights for future clinical investigation and regulatory decision making.